期刊文献+

以α甘露聚糖肽为佐剂的EV71全病毒灭活抗原黏膜免疫小鼠的抗体应答 被引量:4

Immunization response of enterovirus 71 whole virus inactivation antigen combined with PA adjuvant by nasal mucosa in mice
下载PDF
导出
摘要 目的肠道71型全病毒灭活抗原(EV71Ag)联合α-甘露聚糖肽(PA)佐剂滴鼻免疫,观察全身免疫应答及持续时间。方法5—6周龄BALB/c雌性小鼠随机分为阴性对照组,阳性对照组,高剂量疫苗组,低剂量疫苗佐剂组和高剂量疫苗佐剂组,每组10只。阴性对照组以PBS滴鼻,阳性对照组以EV71Ag肌注给药,免疫组以EV71Ag单独和不同剂量分别配伍PA滴鼻给药。首次给药后第0、2、3、4、5和6周采集血清及鼻肺灌洗液,ELISA法检测血清特异性IgG抗体水平及鼻肺灌洗液sIgA抗体水平,MTr法检测淋巴细胞增殖,中和抗体实验检测小鼠血清中和抗体水平。结果各滴鼻组小鼠血清中均产生一定水平的特异性IgG抗体,高剂量疫苗佐剂组第三次免疫后其血清IgG(2.477±0.500)可达到阳性对照组(3.040±0.120)的80%,佐剂组体外淋巴细胞增殖率较阳性对照组有显著增高(P〈0.05),各滴鼻组血清中和抗体滴度均〉8。结论EV71全病毒灭活联合仪.甘露聚糖肽佐剂免疫小鼠可诱导全身免疫应答,且α-甘露聚糖肽佐剂可增强其作用。 Objective To study the systemic immune response of animals immunized by type 71 virus antigen (EV71 Ag) combined with alpha mannan peptide (PA) adjuvant. Methods Forty BALB/c mice of five to six weeks old were randomly divided into five groups. Immune groups accepted EV71 Ag with or without adjuvants. Blood serum and bronchoalveolar lavages were collected at 0,2,3,4,5 and 6 weeks since the first immune treat- ment. The level of IgG, IgA and neutralizing antibody in serum was detected by enzyme-linked immunosorbent assay (ELISA) and Neutralizing antibody tests repectively. MTT assay was involved to assess the proliferation of lympho- cyte. Results The specific IgG antibody in serum was detected in all groups. There was no statistically significant different between the high-dose adjuvanted group and EV71 Ag intramuscular injecting group (2. 477±0. 500 vs 3.040± 0. 120). EV71 Ag combined with alpha mannan peptide (PA)adjuvant caused lymphocyte proliferation invitro, neutralizing antibody titer increased in all groups. There were no significant difference between high-dose adju- vanted group and the EV71 Ag intramuscular injuecting group. Conclusions EV71 Ag combined with alpha man- nan peptide(PA) adjuvant intranasally induced an effective systemic immune reponse.
出处 《基础医学与临床》 CSCD 北大核心 2013年第11期1435-1439,共5页 Basic and Clinical Medicine
基金 国家高技术研究发展计划(863计划)(2012AA02A406)
关键词 黏膜免疫 EV71 中和抗体 特异性IGG抗体 sIgA抗体 淋巴细胞增殖率 mucosal immunity enterovirus 71 antigen neutralizing antibody specific IgG antibody sIgA antibody lymphocyte pro- liferation
  • 相关文献

参考文献15

  • 1Wang SM, Ho TS, Lin HC, et al. Reemerging of enterovirus 71 in Taiwan:the age impact on disease severity [ J ]. Eur J Clin Microbiol Infect Dis, 2012,31:1219 - 1224.
  • 2宋刚,干信.甘露聚糖肽生物活性的研究进展[J].化学与生物工程,2007,24(4):14-16. 被引量:43
  • 3成月英,郭彦聪,张敬国.甘露聚糖肽调节免疫功能的研究近况[J].中国医药导刊,2008,10(5):706-707. 被引量:42
  • 4郭冬生,彭小兰,司国利.免疫增强剂多抗甲素的作用机理及其研究进展[J].兽药与饲料添加剂,2003,8(2):15-16. 被引量:18
  • 5宫惠琳,徐长福,莫立平,张健.多抗甲素对树突状细胞瘤苗体外抗肿瘤活性的影响[J].肿瘤防治研究,2009,36(6):479-482. 被引量:4
  • 6Zhu FC, Wang H, Fang HH, et al. A novel influenze A ( H1N1 )vaccine in various age groups[ J]. N Engl J Med, 2009,361:2412 - 2423.
  • 7Prokesova L, Mlckova P, Stankova I, et al. Immunostimula- tory effect of bacillus firmus on mouse lymphocytes[ J ]. Fo- lia Microbiol,2002,47 : 193 - 197.
  • 8Wu D, Ke CW, Li W, et al. A large outbreak of hand, foot, and mouth disease caused by EV71 and CAV16 in Guang-dong,China,2009 [ J]. Orifinal Article arch virol, 2011, 156 : 945 - 953.
  • 9Chan LG, Parashar UD, Lye MS, et al. Deaths of children during an outbreak of hand,foot,and mouth disease in Sara- wak, malaysia: clinical and pathological characteristics of the disease[ J]. Clin Infeet Dis,2000,31:678 - 683.
  • 10Hognesch H. Mechanisms of stimulation of the immune re- sponseby aluminum adjuvants [ J ]. Vaccine, 2002, 20 : 34 - 39.

二级参考文献109

共引文献112

同被引文献46

  • 1宋刚,干信.甘露聚糖肽生物活性的研究进展[J].化学与生物工程,2007,24(4):14-16. 被引量:43
  • 2曾祥元,廖宗志,马布仁,等.多抗甲素免疫活性的实验研究[J].抗生素,1985;1:43-46.
  • 3ARUMUGAM T U,ITO D,TAKASHIMA E,et al.Application of wheat germ cell-free protein expression system for novel malaria vaccine candidate discovery[J].Expert Rev Vaccines,2014,13(1):75-85.
  • 4CAI Q L,PENG G Y,BU L Y,et al.Immunogencity and in vitro protective efficacy of a polyepitope Plasmodium falciparum candidate vaccine constructed by epitope shuffling[J].Vaccine,2007,25(28):5155-5165.
  • 5WANG J,LIN Y H,CAI P F,et al.Effects of vector fusion peptides on the conformation and immune reactivity of epitopeshuffled,recombinant multi-epitope antigens[J].Protein Pept Lett,2011,18(1):73-83.
  • 6国家药品监督管理局.国家药品标准(药典、国家标准)颁布件[2000国药标字XG_056号][J].中国药品标准,2003,4(4):20-22.
  • 7World Health Organization.World malaria report 2014[EB/OL].(2014-12-09)[2015-04-01].http://www.who.int/malaria/publications/world_malaria_report_2014/en/.ISBN:9789-241564830.
  • 8ARAMA C,TROYE-BLOMBERG M.The path of malaria vaccine development:challenges and perspectives[J].J Intern Med,2014,275(5):456-466.
  • 9HOGNESCH H.Mechanism of immunopotentiation and safety of aluminum adjuvants[J].Front Immunol,2013,3(1):406.
  • 10DUCLOS P.Safety of immunization and adverse events following vaccination against hepatitis B[J].J Hepatol,2003,39(Suppl 1):S83-S88.

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部